Efficacy of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in CKD Patients on Peritoneal or Hemo Dialysis: The Middle-East Experience

Abstract

Background: Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet hydrochloride acts on the calcium-sensing receptors to increase its sensitivity to calcium, thereby reducing parathyroid hormone (PTH) secretion. Calcimimetics lower parathyroid hormone levels without increasing calcium and phosphorus levels.

Intermittent Dosing of Cinacalcet is also Effective in Treating Secondary Hyperparathyroidism in Hemodialysis Patients

“…This breakthrough in the pharmacological management of SHPT has been corroborated in different population subgroup, including our previous study in the middle-east dialysis population, where once daily cinacalcet effectively decreased the PTH values in hemodialysis and peritoneal dialysis patients with SHPT [11].…”

“…In our previous study, we have shown the effectiveness of cinacalcet therapy compared to conventional treatment in controlling SHPT in dialysis patients [11]. In the present study we had taken up the issue of a different dosing regimen of cinacalcet applicable to the same patient population.…”

“…This study is the extension of our previous study [11], and was conducted at King Fahd Hospital of the University, Al Khobar, Saudi Arabia after being approved by our Institutional Ethics Committee. The study was conducted according to the Helsinki declaration and carried out over a period of one year (June 2011 to May 2012).…”